Editor’s Comment
Medwave 2014;14(5):e5968 doi: 10.5867/medwave.2014.05.5968

Introducing a new series: Evidence-based decision-making

Presentando una nueva serie: La evidencia para las decisiones en salud

Autora: Vivienne C. Bachelet
Filiación: Editora Jefe, Medwave
E-mail: vbachelet@medwave.cl

Fecha de publicación: 11/6/2014

Resumen

Se presenta una paciente a su consulta aquejada de ideas persistentes e intrusivas que le impiden llevar adelante sus tareas cotidianas y que le causan bastante angustia. Usted le aplica un cuestionario simple y concluye que posiblemente tiene un trastorno obsesivo compulsivo. El estudio de rigor descarta otras causas menos frecuentes de cuadros similares y una evaluación diagnóstica estandarizada formal confirma su sospecha clínica. ¿Cuáles son los mejores tratamientos disponibles para ofrecer a su paciente y qué grado de éxito tienen (…)

Abstract

A patient comes to your office with repeated unwanted and intrusive thoughts that prevent her from conducting her daily life activities and that make her anxious. You apply a simple screening and conclude that she may have an obsessive-compulsive disorder. The work-up rules out other less frequent causes of similar manifestations and a more formal diagnostic interview confirms your clinical suspicion. What are the best treatment options you can offer your patient and how successful are they? (…)

Previously in the Journal we have referred to the changes in the paradigm of systematic reviews, the hallmark of evidence-based medicine [2],[3],[4]. These result from the growing importance of publication bias (when studies with favorable results are published more often than those with unfavorable results) and other problems that are appearing in biomedical literature [5],[6],[7],[8],[9],[10],[11]. We can even conclude that the way in which evidence-based medicine is practiced is becoming obsolete. New approaches to evidence are emerging and instead of reading articles and doing critical analysis, a need for readily available reliable summaries is increasingly becoming apparent. The CAT (critically appraised topic) already published this month is a case in point (doi: 10.5867/medwave.2014.05.5964). Aligned with this tendency are current efforts to enhance the quality of clinical practice guidelines. The GRADE group (Grading of Recommendations Assessment, Development and Evaluation Working Group) and the Cochrane Collaboration have been leaders in clinical guidelines and systematic reviews, respectively.

In spite of the limitations mentioned above, we can reasonably conclude that today’s evidence base is far sounder that what was available 20 or 40 years ago. Information technologies and internet have allowed virtually real-time exchange of scientific research advances, making it less likely to hear expressions such as “there is no evidence for.” It is now clear that the dichotomy “there is evidence” / “there is no evidence” does not work. Medicine is much more complex than that. Today we need to know about the benefits and harms of therapy; reliability of existing research; and how we can provide reasonably trustworthy statistics for our patients. This will help in the process of deciding the best course of action for a given patient, in a given setting.
It was not more than 15 years ago that the emphasis was placed on continuing medical education. Now, however, we speak of knowledge translation, a developing science that aims to overcome the gap between what we know and what we practice, as well as overcoming barriers to implement evidence-based practice [12].

Introducing in *Medwave* a new series called “Evidence-based decision-making” with the purpose of guiding the clinician in the process of making decisions based on the best available evidence. The series will begin with an article authored by professors Ignacio Neumann and Gabriel Rada (doi: 10.5867/medwave.2014.05.5966). Both are members of the GRADE group and the Cochrane Collaboration. Gabriel Rada is also co-director of the Southern American Branch of the Iberoamerican Cochrane Centre. The standing of our authors in the most important international forums on topics such as development of clinical guidelines and evidence reviews for meta-analysis allows us to have the best contributions for our journal. The series will provide essential concepts for the decision-making process in healthcare and will deal with issues such as when it is worthwhile to decide, how to interpret results and what is their reliability, how to translate evidence into clinical decisions and how to take it to the practical context of the patient sitting before us. As with the series “Topics and controversies in biostatistics” that we recently initiated, this series has a beginning but no predetermined ending. The nature of the disciplinary evolution will tell us how to proceed.

Back to our patient with obsessive-compulsive disorder mentioned in the beginning of this editorial. NICE (National Institute for Health and Clinical Excellence) issued a clinical guideline in 2005 [13] with recommendations based on 17 controlled studies that suggests that cognitive behavioral intervention is effective and that there is good evidence for selective serotonin reuptake inhibitors and clomipramine, but associated to potential harms, and what is the quality of the evidence. When combining these two components it will be possible to inform the patient so that she may decide on the best possible evidence, bringing into play her own beliefs and her practical possibilities in accordance with her own life project.

**Notes**

Declaración de conflictos de intereses

VCB declara no tener potenciales conflictos de intereses con la materia de este artículo.

**Agradecimientos**

La autora agradece a Gabriel Rada por haber ayudado con algunas ideas centrales expresadas en este editorial.

**Referencias**

4. Bachelet VC. The Tamiflu saga continues: will our conduct change after the publication of the latest systematic review on benefits and harms of oseltamivir? Medwave. 2014;14(04):e5953. | CrossRef |
8. Rada G. The requirement to disclose individual patient data in clinical studies will bring down the wall behind which the pharmaceutical industry hides the truth: the Kerkoporta is ajar. Medwave. 2013;13(05):e5735. | CrossRef |